Our Partners

General Criteria

Funds Available for Clinical Research, including Outcome Evaluation

The Canadian Hemophilia Society, in collaboration with Pfizer Canada (formerly Wyeth), has established the Care Until Cure research program to support clinical research, including outcome evaluation, to improve the quality of life of persons with hemophilia and other inherited bleeding disorders.


Applicants must be Canadian citizens or permanent residents and affiliated with a Canadian university or not-for-profit health-related organization. Grants will be made available for clinical research, including outcome evaluation, in fields relevant to improving the quality of life of:
  • persons with hemophilia
  • persons with von Willebrand disease or other inherited bleeding disorders
  • persons with related conditions such as HIV or hepatitis C infection
  • carriers of an inherited bleeding disorder.

For the 2018-2019 granting period of the program, specific areas of interest have been identified and investigators are encouraged to submit proposals within these areas. The grants review committee will allocate funding to the strongest and most relevant projects included but not limited to the areas of interest listed below.

2018-2019 AREAS OF INTEREST include and are not limited to:

  • Hemophilia B

1. Epidemiology / burden of disease / outcome research
2. Routine prophylaxis and preventative treatment
3. Surgical prophylaxis, dosing
4. Pharmacokinetics (including recovery) in Hem B
5. Joint outcomes and optimizing therapy
6. The role of non-circulating & extravascular Factor IX in hemostasis
7. Mild Hemophilia B: clinical outcomes, healthcare utilization, joint surveillance
8. “Real World” Observational Data on Factor Utilization & Cost-effectiveness

  • Transition and clinical issues

1. Treatment adherence to prescribed regimens
2. Management of adolescent hemophilia patients
3. Management of aging hemophilia population
4. Tailoring/Personalized Hemophilia Treatment (eg, pharmacokinetics and other factors)

  • Clinical monitoring of hemophilia treatment

1. Inhibitors, Inhibitor Management (eg, Immune tolerance), and Immunogenicity

  • Product switching experience

1. Rationale for switching products
2. Inhibitor development and safety associated with switches
3. Understanding differences in Factor VIII molecules (eg, full-length versus B-domain deleted)

  • Antifibrinolytic Therapy

Location of Tenure

The research will be conducted in Canada by Canadian researchers affiliated with Canadian universities and not-for-profit health-related organizations.

Grant amount / Duration of Support

Individual grants valued at $75,000 per year and per project will be awarded to researchers for a maximum of $150,000 which can be expended over 2 or 3 years. If a two year award is provided, the second year of funding is dependent on evidence of progress as described in the required progress report. Grant funding will begin on April 1, 2018.

Yearly grants will normally be disbursed in two payments in each year.

General Conditions and Application Form

Applications must be completed and submitted electronically to the Canadian Hemophilia Society and one (1) original paper copy, including signatures, must be sent to the National Office of the Canadian Hemophilia Society:

666 Sherbrooke Street West, Suite 301, Montreal, QC H3A 1E7

Please click on the following links for General Conditions and Application Form.


All completed application forms and support documents must arrive at the National Office of the Canadian Hemophilia Society on or before November 15, 2017. If the CHS receives the application after the deadline date but it is postmarked on or before the deadline date, then it is considered to have been submitted on time. The names of the winners of the grants will be announced by March, 2018.


Applications will be reviewed by an independent peer review committee composed of Canadian medical and healthcare professionals and a patient representative. This committee will rank the applications and will make recommendations to the CHS Board of Directors on funding of the proposals. The final decisions regarding awards will be made by the CHS Board of Directors. No appeals will be considered.